Are you Dr. Styles?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 43 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
747 52nd St
Oakland, CA 94609Phone+1 510-428-3372Fax+1 510-601-3916
Summary
- Dr. Lori Styles, MD is a pediatric hematologist/oncologist in Oakland, California. She is currently licensed to practice medicine in California. She is affiliated with UCSF Benioff Children's Hospital Oakland, Alta Bates Summit Medical Center-Alta Bates Campus, and John Muir Medical Center, Walnut Creek.
Education & Training
- Children's Hospital-OaklandFellowship, Pediatric Hematology/Oncology, 1993 - 1996
- Children's Hospital-OaklandResidency, Pediatrics, 1989 - 1992
- University of California San Diego School of MedicineClass of 1989
Certifications & Licensure
- CA State Medical License 1990 - 2016
Clinical Trials
- Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients Start of enrollment: 2001 Aug 01
- Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease Start of enrollment: 2012 Feb 01
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease Start of enrollment: 2014 Jul 14
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsIbrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.David Bernard Miklos, Mohammad Abu Zaid, Julian P Cooney, Jörn C Albring, Mary Flowers
Journal of Clinical Oncology. 2023-04-01 - 387 citationsIbrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, ope...Carol Moreno, Richard Greil, Fatih Demirkan, Alessandra Tedeschi, Bertrand Anz
The Lancet. Oncology. 2019-01-01 - 22 citationsSingle-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Carolyn Owen
American Journal of Hematology. 2018-11-01
Press Mentions
- FDA Accepts Ibrutinib Application for GVHDApril 4th, 2017